Qian Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qian Zhou has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Hai-Bin Luo
Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou, China
20 shared publications - Yinuo Wu
State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
13 shared publications Chen Zhang
School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China
10 shared publicationsZhe Li
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China
10 shared publicationsYi-You Huang
Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou, China
7 shared publications- Chen Zhang
School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China
6 shared publications
Latest Publications
- 15 October 2026
- Published by Springer Nature in International Journal Of Impotence Research
- p. 1-12
Exploring extracts from Wendlandia Uvariifolia Subsp. Chinensis (Merr.) Cowan as natural phosphodiesterase type 5 inhibitors with preclinical anti-erectile dysfunction activity
Wendlandia uvariifolia subsp. chinensis (Merr.) Cowan is a traditional medicinal plant used by the Li ethnic group in Hainan Province, China, for the treatment of herpes zoster. However, its pharmacological properties remain unclear. This study aimed to evaluate its phosphodiesterase type 5 inhibitory activity, identify the active components, and explore its therapeutic potential for erectile dysfunction. Through high-throughput screening of 1200 traditional Chinese herbal medicines, this plant was identified as a potential phosphodiesterase type 5 inhibitor. Bioactivity-guided fractionation and gas chromatography–mass spectrometry analysis identified the petroleum ether fraction as the most active fraction, while phytol, one of its identified constituents, inhibited phosphodiesterase type 5 in vitro with an IC₅₀ value of 2.5 ± 0.1 μmol/L. In H₂O₂-injured endothelial cells, petroleum ether fraction significantly restored nitric oxide production. In a paroxetine-induced erectile dysfunction rat model, the fraction improved sexual behavior parameters, restored NO/cGMP signaling, and alleviated pathological remodeling and fibrosis in the corpus cavernosum. In a diabetes mellitus-associated erectile dysfunction rat model, the fraction also improved corpus cavernosum architecture, increased smooth muscle content, and reduced fibrosis, although the increase in the intracavernous pressure/mean arterial pressure ratio did not reach statistical significance. Overall, the results suggest the preclinical anti-erectile dysfunction potential of petroleum ether fraction and support its further mechanistic, pharmacokinetic, safety, and translational evaluation.
- 15 October 2026
- Published by Springer Nature in International Journal Of Impotence Research
- p. 1-12
Exploring extracts from Wendlandia Uvariifolia Subsp. Chinensis (Merr.) Cowan as natural phosphodiesterase type 5 inhibitors with preclinical anti-erectile dysfunction activity
Wendlandia uvariifolia subsp. chinensis (Merr.) Cowan is a traditional medicinal plant used by the Li ethnic group in Hainan Province, China, for the treatment of herpes zoster. However, its pharmacological properties remain unclear. This study aimed to evaluate its phosphodiesterase type 5 inhibitory activity, identify the active components, and explore its therapeutic potential for erectile dysfunction. Through high-throughput screening of 1200 traditional Chinese herbal medicines, this plant was identified as a potential phosphodiesterase type 5 inhibitor. Bioactivity-guided fractionation and gas chromatography–mass spectrometry analysis identified the petroleum ether fraction as the most active fraction, while phytol, one of its identified constituents, inhibited phosphodiesterase type 5 in vitro with an IC₅₀ value of 2.5 ± 0.1 μmol/L. In H₂O₂-injured endothelial cells, petroleum ether fraction significantly restored nitric oxide production. In a paroxetine-induced erectile dysfunction rat model, the fraction improved sexual behavior parameters, restored NO/cGMP signaling, and alleviated pathological remodeling and fibrosis in the corpus cavernosum. In a diabetes mellitus-associated erectile dysfunction rat model, the fraction also improved corpus cavernosum architecture, increased smooth muscle content, and reduced fibrosis, although the increase in the intracavernous pressure/mean arterial pressure ratio did not reach statistical significance. Overall, the results suggest the preclinical anti-erectile dysfunction potential of petroleum ether fraction and support its further mechanistic, pharmacokinetic, safety, and translational evaluation.
- Open Access
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Discovery of PDE4 Inhibitory Constituents from an Edible Fruit (Citrus medica L. var. sarcodactylis Swingle) Using an AI-Assisted Screening Strategy
Chronic inflammatory diseases are a leading cause of global mortality. Phosphodiesterase 4 (PDE4) plays a key role in regulating inflammation, and dietary components with PDE4 inhibitory activity offer potential for supporting health through nutritional strategies. In this study, we constructed a compound library derived from 108 edible plants and developed an AI-assisted multi-step screening strategy integrating molecular docking and in vitro validation. The fruit of Citrus medica L. var. sarcodactylis Swingle (fingered citron, FC) was identified as a novel source of PDE4-inhibitory activity, and seven constituent compounds were characterized as natural PDE4 inhibitors.. Cellular experiments demonstrated that both the crude extract and isolated compounds reduced iNOS expression and decreased levels of the pro-inflammatory cytokines TNF-α and IL-1β.. This work presents a generally applicable AI-assisted strategy for screening bioactive food compound and highlights fingered citron as a promising functional food fcandidate.
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDiscovery of PDE4 Inhibitory Constituents from an Edible Fruit (Citrus medica L. var. sarcodactylis Swingle) Using an AI-Assisted Screening Strategy
Chronic inflammatory diseases are a leading cause of global mortality. Phosphodiesterase 4 (PDE4) plays a key role in regulating inflammation, and dietary components with PDE4 inhibitory activity offer potential for supporting health through nutritional strategies. In this study, we constructed a compound library derived from 108 edible plants and developed an AI-assisted multi-step screening strategy integrating molecular docking and in vitro validation. The fruit of Citrus medica L. var. sarcodactylis Swingle (fingered citron, FC) was identified as a novel source of PDE4-inhibitory activity, and seven constituent compounds were characterized as natural PDE4 inhibitors.. Cellular experiments demonstrated that both the crude extract and isolated compounds reduced iNOS expression and decreased levels of the pro-inflammatory cytokines TNF-α and IL-1β.. This work presents a generally applicable AI-assisted strategy for screening bioactive food compound and highlights fingered citron as a promising functional food fcandidate.
- Open Access
Integrated Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulations Accelerate the Discovery of Novel PDE1 Inhibitors with Potential for the Treatment of Idiopathic Pulmonary Fibrosis
Phosphodiesterase-1 (PDE1) represents an attractive target for the treatment of idiopathic pulmonary fibrosis (IPF). However, the limited chemical diversity of current PDE1 inhibitors has hindered the development of potential anti-IPF drugs, primarily due to an ambiguous understanding of interactions between inhibitors and PDE1. Herein, we report an integrated virtual screening strategy containing pharmacophore modeling, molecular docking, and molecular dynamics simulations, which markedly accelerated the discovery of novel PDE1 inhibitors. Enzymatic assays identified eleven active compounds with moderate inhibition from twenty-six purchased candidates, encompassing nine distinct scaffold types. Notably, 6484-0008 and 6484-0032 exhibited more than 50% inhibition at a concentration of 1 ÎĽM. Hydrogen bond analysis and residue-based energy decompositions revealed key recognition mechanisms involving crucial residues Gln421, His373, and Phe424, as well as the unique Thr271 in the flexible H-loop region, providing insights for the rational design of inhibitors with enhanced potency.
Open AccessIntegrated Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulations Accelerate the Discovery of Novel PDE1 Inhibitors with Potential for the Treatment of Idiopathic Pulmonary Fibrosis
Phosphodiesterase-1 (PDE1) represents an attractive target for the treatment of idiopathic pulmonary fibrosis (IPF). However, the limited chemical diversity of current PDE1 inhibitors has hindered the development of potential anti-IPF drugs, primarily due to an ambiguous understanding of interactions between inhibitors and PDE1. Herein, we report an integrated virtual screening strategy containing pharmacophore modeling, molecular docking, and molecular dynamics simulations, which markedly accelerated the discovery of novel PDE1 inhibitors. Enzymatic assays identified eleven active compounds with moderate inhibition from twenty-six purchased candidates, encompassing nine distinct scaffold types. Notably, 6484-0008 and 6484-0032 exhibited more than 50% inhibition at a concentration of 1 ÎĽM. Hydrogen bond analysis and residue-based energy decompositions revealed key recognition mechanisms involving crucial residues Gln421, His373, and Phe424, as well as the unique Thr271 in the flexible H-loop region, providing insights for the rational design of inhibitors with enhanced potency.
- Open Access
- 17 April 2026
- Published by MDPI AG in Preprints.org
Integrated Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulations Accelerate the Discovery of Novel PDE1 Inhibitors with Potential for the Treatment of Idiopathic Pulmonary Fibrosis
Phosphodiesterase-1 (PDE1) represents an attractive target for the treatment of idiopathic pulmonary fibrosis (IPF). However, the limited chemical diversity of current PDE1 inhibitors has hindered the development of potential anti-IPF drugs, primarily due to an ambiguous understanding of interactions between inhibitors and PDE1. Herein, we report an integrated virtual screening strategy containing pharmacophore modeling, molecular docking, and molecular dynamics simulations, which markedly accelerated the discovery of novel PDE1 inhibitors. Enzymatic assays identified eleven active compounds with moderate inhibition from twenty-six purchased candidates, encompassing nine distinct scaffold types. Notably, 6484-0008 and 6484-0032 exhibited more than 50% inhibition at a concentration of 1 ÎĽM. Hydrogen bonding analysis and residue-based energy decompositions revealed key recognition mechanisms involving crucial residues Gln421, His373, and Phe424, as well as the unique Thr271 in the flexible H-loop region, providing insights for the rational design of inhibitors with enhanced potency.
- 17 April 2026
- Published by MDPI AG in Preprints.org
Open AccessIntegrated Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulations Accelerate the Discovery of Novel PDE1 Inhibitors with Potential for the Treatment of Idiopathic Pulmonary Fibrosis
Phosphodiesterase-1 (PDE1) represents an attractive target for the treatment of idiopathic pulmonary fibrosis (IPF). However, the limited chemical diversity of current PDE1 inhibitors has hindered the development of potential anti-IPF drugs, primarily due to an ambiguous understanding of interactions between inhibitors and PDE1. Herein, we report an integrated virtual screening strategy containing pharmacophore modeling, molecular docking, and molecular dynamics simulations, which markedly accelerated the discovery of novel PDE1 inhibitors. Enzymatic assays identified eleven active compounds with moderate inhibition from twenty-six purchased candidates, encompassing nine distinct scaffold types. Notably, 6484-0008 and 6484-0032 exhibited more than 50% inhibition at a concentration of 1 ÎĽM. Hydrogen bonding analysis and residue-based energy decompositions revealed key recognition mechanisms involving crucial residues Gln421, His373, and Phe424, as well as the unique Thr271 in the flexible H-loop region, providing insights for the rational design of inhibitors with enhanced potency.
- Open Access
Molecular Dynamics-Assisted Discovery of Novel Phosphodiesterase-5 Inhibitors Targeting a Unique Allosteric Pocket
Phosphodiesterase-5 (PDE5) is a potent therapeutic target for the treatment of male erectile dysfunction and pulmonary arterial hypertension with several drugs available on the market. However, most of the reported PDE5 inhibitors lack specificity over PDE6, a holoenzyme in eleven PDE families, which may cause various adverse effects. Targeting a unique allosteric pocket has proved to be an effective approach to designing selective PDE5 inhibitors. In the present study, an integrated virtual screening procedure consisting of pharmacophore modeling screening, molecular docking, molecular dynamics simulations, and binding free energy calculations was applied to the discovery of novel PDE5 inhibitors targeting the allosteric pocket. Seven out of thirty-three molecules purchased from the SPECS database (a hitting accuracy of 21%) with novel scaffolds were PDE5 inhibitors with enzymatic inhibition ratios of more than 50% at a concentration of 10 ÎĽM. Predicted binding patterns indicate these hits fit well in the allosteric pocket in PDE5. In particular, compound AI-898/12177002 (IC50 = 1.6 ÎĽM) demonstrates over 10-fold selectivity towards PDE6, providing a novel scaffold for the optimization of potent and selective PDE5 inhibitors with less adverse effects.
Open AccessMolecular Dynamics-Assisted Discovery of Novel Phosphodiesterase-5 Inhibitors Targeting a Unique Allosteric Pocket
Phosphodiesterase-5 (PDE5) is a potent therapeutic target for the treatment of male erectile dysfunction and pulmonary arterial hypertension with several drugs available on the market. However, most of the reported PDE5 inhibitors lack specificity over PDE6, a holoenzyme in eleven PDE families, which may cause various adverse effects. Targeting a unique allosteric pocket has proved to be an effective approach to designing selective PDE5 inhibitors. In the present study, an integrated virtual screening procedure consisting of pharmacophore modeling screening, molecular docking, molecular dynamics simulations, and binding free energy calculations was applied to the discovery of novel PDE5 inhibitors targeting the allosteric pocket. Seven out of thirty-three molecules purchased from the SPECS database (a hitting accuracy of 21%) with novel scaffolds were PDE5 inhibitors with enzymatic inhibition ratios of more than 50% at a concentration of 10 ÎĽM. Predicted binding patterns indicate these hits fit well in the allosteric pocket in PDE5. In particular, compound AI-898/12177002 (IC50 = 1.6 ÎĽM) demonstrates over 10-fold selectivity towards PDE6, providing a novel scaffold for the optimization of potent and selective PDE5 inhibitors with less adverse effects.
- Open Access
- 21 January 2025
- Published by MDPI AG in Antioxidants
- Vol. 14  (2) , 123
Discovery of Effective Inhibitors Against Phosphodiesterase 9, a Potential Therapeutic Target of Alzheimer’s Disease with Antioxidant Capacities
Alzheimer’s disease (AD) is a widely recognized type of dementia that leads to progressive cognitive decline and memory loss, affecting a significant number of people and their families worldwide. Given the multifactorial nature of AD, multitarget-directed ligands (MTDLs) hold promise in developing effective drugs for AD. Phosphodiesterase-9 (PDE9) is emerging as a promising target for AD therapy. In this study, by combining a PDE9 inhibitor C33 with the antioxidant melatonin, we designed and discovered a series of pyrazolopyrimidinone derivatives that simultaneously inhibit PDE9 and possess antioxidant activities. Molecular docking, together with dynamics simulations, were applied to accelerate compound design and reduce synthetic work. Four out of the 14 compounds were validated as effective PDE9 inhibitors with comparable antioxidant activity. Notably, compounds 17b and 17d demonstrated IC50 values of 91 and 89 nM against PDE9, respectively, with good antioxidant activities (ORAC (Trolox) of 2.00 and 2.60). This work provides a new approach for designing MTDLs for the treatment of AD and offers insights for further structural modifications of PDE9 inhibitors with antioxidant capacities.
- 21 January 2025
- Published by MDPI AG in Antioxidants
- Vol. 14  (2) , 123
Open AccessDiscovery of Effective Inhibitors Against Phosphodiesterase 9, a Potential Therapeutic Target of Alzheimer’s Disease with Antioxidant Capacities
Alzheimer’s disease (AD) is a widely recognized type of dementia that leads to progressive cognitive decline and memory loss, affecting a significant number of people and their families worldwide. Given the multifactorial nature of AD, multitarget-directed ligands (MTDLs) hold promise in developing effective drugs for AD. Phosphodiesterase-9 (PDE9) is emerging as a promising target for AD therapy. In this study, by combining a PDE9 inhibitor C33 with the antioxidant melatonin, we designed and discovered a series of pyrazolopyrimidinone derivatives that simultaneously inhibit PDE9 and possess antioxidant activities. Molecular docking, together with dynamics simulations, were applied to accelerate compound design and reduce synthetic work. Four out of the 14 compounds were validated as effective PDE9 inhibitors with comparable antioxidant activity. Notably, compounds 17b and 17d demonstrated IC50 values of 91 and 89 nM against PDE9, respectively, with good antioxidant activities (ORAC (Trolox) of 2.00 and 2.60). This work provides a new approach for designing MTDLs for the treatment of AD and offers insights for further structural modifications of PDE9 inhibitors with antioxidant capacities.
- 30 October 2024
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36  (8)
Structure-based optimization of isoaurostatin as novel PDE4 inhibitors with anti-fibrotic effects
- 30 October 2024
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36  (8)
Structure-based optimization of isoaurostatin as novel PDE4 inhibitors with anti-fibrotic effects
- 18 May 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 149, 107474
Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis
- 18 May 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 149, 107474
Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis
- 1 May 2024
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36  (4)
Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects
- 1 May 2024
- Published by Elsevier in Chinese Chemical Letters
- Vol. 36  (4)
Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects